Thymosin alpha-1

Thymosin alpha-1 is a fragment of a protein produced by the thymus, the gland that trains immune cells. It sits in an unusual position: a licensed medicine in more than thirty countries, and a research compound in the US and UK.

That split is what makes it worth reading about carefully.

Why people are talking about it#

Because it has a genuine clinical record. Randomised trials in hepatitis and sepsis, and approvals from more than thirty national regulators, put it well ahead of almost everything else in this category on evidence.

The mechanism is also easy to find compelling. The thymus trains immune cells and its output declines steeply with age, so a signalling fragment from that gland is a natural candidate for immune support.

What people take it for#

In countries where it is licensed, it is used clinically alongside treatment for hepatitis B and C, and as immune support in sepsis and some cancers. It was studied during the COVID-19 pandemic.

The wellness market sells it for something rather different: frequent colds, chronic fatigue, and general immune support in otherwise healthy people.

Chronic hepatitis#

This is the licensed use in most countries where it is approved. The mechanism is modulation of T cell maturation and function, which is what the thymus does.

In practice that describes helping the immune system mount a more organised response to a virus it is failing to clear. Randomised trials in hepatitis B and C have reported modest benefits, generally in combination with other treatment.

Sepsis and critical illness#

The claim is better survival in patients whose immune systems have become dysregulated, on the same T cell modulation applied where the response has gone wrong in both directions at once.

Trials in sepsis have been run, including a large one in China, with results reviewers have described as promising rather than conclusive.

General immune support#

The claim is fewer colds and more resilience in a healthy person. That is the use with the least evidence behind it, and it is the one most of the market is built on.

What the evidence shows#

More than most compounds in this section. There are randomised trials in hepatitis and in sepsis, reviews have generally found it well tolerated with modest benefits in specific clinical settings, and more than thirty national regulators have assessed and approved it for something.

The evidence for everyday wellness use is thinner. Studies in unwell hospital patients say little about whether a healthy adult gets fewer colds, and no good trial has asked that question. The COVID-19 work followed the same pattern: observational and small controlled studies suggesting benefit in severe disease, without a large definitive trial.

Injection site reactions are the most common report, along with occasional flu-like symptoms in the first days.

How it is taken#

A subcutaneous injection, prescribed and dosed by a clinician in the countries where it is licensed. Clinical courses are defined by the condition being treated rather than taken open-endedly.

How it compares#

Against thymulin#

Thymulin is the other thymic peptide sold in this category. Thymosin alpha-1 has randomised trials, current use and approvals; thymulin's human record is from the 1980s.

Against its own licensed use#

The most useful comparison is internal. The same compound has good evidence in hepatitis and essentially none for a healthy adult wanting fewer colds, and the gap between those two is the whole story of this page.

Common questions#

Is it approved?

In more than thirty countries, for hepatitis and related uses. Not in the US or UK.

Does it stop me getting colds?

No trial has tested that. The evidence concerns unwell hospital patients.

What does the thymus actually do?

It trains T cells to recognise threats. Its output declines steeply with age, in a process called thymic involution.

Was it useful in COVID?

Small and observational studies suggested benefit in severe disease. A definitive trial was not completed.